Opus Genetics (IRD) Enterprise Value (2010 - 2026)

Opus Genetics (IRD) has 17 years of Enterprise Value data on file, last reported at -$60.0 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 43.56% year-over-year to -$60.0 million in Q1 2026; TTM through Mar 2026 was -$60.0 million, a 43.56% decrease from a year earlier, with the FY2025 full-year figure at -$45.1 million, down 48.7% from the prior year.
• Enterprise Value for Q1 2026 stood at -$60.0 million, down from -$45.1 million in the prior quarter.
• Over the last five years, Enterprise Value for IRD reached as high as -$14.0 million in Q3 2022 and fell as low as -$60.0 million in Q1 2026.
• Historically, Enterprise Value has averaged -$37.1 million across 5 years, with a median of -$40.0 million in 2023.
• Across the five-year window, Enterprise Value sank 203.53% in 2023 and soared 39.97% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$42.7 million in 2022, then retreated by 18.35% to -$50.5 million in 2023, then surged by 39.97% to -$30.3 million in 2024, then sank by 48.7% to -$45.1 million in 2025, then slumped by 33.06% to -$60.0 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$60.0 million in Q1 2026, -$45.1 million in Q4 2025, and -$30.8 million in Q3 2025.